Minerva IPO Presentation Deck

Comparison to FDA assigned OPC (Objective Performance Criteria) Minerva Efficacy was "Statistically Significantly Greater" Compared to OPC Control Group¹ Company Device Name Energy Uterine anatomy Mean procedure time Amenorrhea rate* zero bleeding Success rate** Snormal bleeding Hysterectomy rate (36-mo. post treatment) Minerva Surgical Minerva ES PlasmaSense Normal 3.1 min 71.6% 91.8% 0.9% Hologic Novasure Radio Frequency Normal 5 min 36.0% 77.7% 6.3% Objective Performance Criteria Group J&J ! Ethicon Inc. ThermaChoicet Hot Water Balloon Cooper Minerva I Surgical I Surgical Her Option Cryoablation Normal >10 min 22.0% 67.4% 8.3% I Genesys HTA Heated Saline Normal and Abnormal 26.4 min 35.0% 68.4% 10.2% Source: FDA approved efficacy rates- Instructions for Use and Summary of Safety and Effectiveness Data *At 12-month follow up; amenorrhea is ZERO bleeding **At 12-month follow up; success rate is defined as s normal bleeding level, based on PBLAC diary scores * Minerva pivotal study control group for Minerva ES was the FDA-assigned OPC (Objective Performance Criteria). Control group patients for Novasure, Her Option, Genesys HTA, ThermaChoice, and MEA studies were all treated with rollerball endometrial ablation. I I I I Normal 27.4 min 13.2% 80.2% 8.6% Microsulis Medical Ltd. MEAT Microwave Normal 3.45 min 55.3% 87% no data available † Product no longer on the market 19

View entire presentation